Patent intelligence · US
US 10323026
Heterocyclic compound
Heterocyclic compound
Patent details — US 10323026
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 18, 2019
- Expiration
- Jun 13, 2039
- Applicant
- Takeda Pharmaceutical Company Limited
- Claims
- 10
- CPC classes
- A61P, A61P21/02, A61P25/00, A61P25/04
Quick answer
US 10323026 (Heterocyclic compound) is held by Takeda Pharmaceutical Company Limited. Status: granted. Granted Jun 18, 2019. Expires Jun 13, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61P, A61P21/02, A61P25/00, A61P25/04, A61P25/08, A61P25/14
More from Takeda Pharmaceutical Company Limited
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Frequently asked questions
What is US patent 10323026?
US 10323026 (Heterocyclic compound) is held by Takeda Pharmaceutical Company Limited. Status: granted. Granted Jun 18, 2019. Expires Jun 13, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10323026?
Takeda Pharmaceutical Company Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 10323026 expire?
Our index shows an expiration date of Jun 13, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.